



Press Release

February 28, 2018

Cambridge, MA & Cali, Colombia -- XBIOSPACE Labs and The Foundation for Sickle Cell Disease from MIT Media Labs are proud to announce today that through our combined efforts and contributions from private and pledged donations, as well as INS governmental grants, we have raised over **750K USD** that will go towards our human clinical trial to treat and cure sickle cell disease!

Furthermore, we announce today that we'll be starting a crowdfunding campaign to raise 5 million USD of which XBIOSPACE will match 2.5 million USD before the end of Spring. Our crowdfunding campaign will go live at the start of our official announcement for this project at the Future of DNA event March 7, 2018.

Moreover, we will be raising an additional 10 million USD through the sale and licensing of our healthcare IT services and products, more updates on that will be coming soon, bringing the total contribution that will go to our human trial, current and future projects, to a total of over 15 million USD.

We will be publishing two publicly available peer reviewed scientific communications; a white paper publication for our blockchain and API The Crescent-Reishi™, a methods and solution to solving Sickle Cell Disease and Age Reversal. In addition, information on recruitment and the timeline for our human clinical trial will be made available at clinicaltrials.gov.

Today we also announce that our CEO Rafael R. Vivas will be traveling to China, India, and Colombia towards the end of March to further cement our international business, governmental, scientific and collaborations.

Lastly, we would also like to announce that we will not be taking anymore private investments until the official announcement on our private fundraising efforts on the Crescent-Reishi™ presale token and ICO but we will continue open communications with private investors interested in XBIOSPACE ideals and mission from our new office in Cambridge, MA:

**485 Massachusetts Avenue
Suite 300
Cambridge, MA 02139**

Initial Press Release

February 26, 2018

XBIOSPACE & La Fundación Integral Para La Drepanocitosis to Partner on the First Decentralized Blockchain Enabled Human Clinical Trial To Cure Sickle Cell Disease Using CRISPR in Latin America

Jacksonville, FL USA, Rourkela, Trivandrum, India, & Cali, Colombia -- XBIOSPACE Labs and La Fundación Integral para la Drepanocitosis (The Colombian Sickle Cell Foundation, The Foundation) announce today that we are partnering on what will be the first decentralized blockchain enabled human clinical trial to cure sickle cell disease using CRISPR in Latin America.

The initial focus will be to develop technological solutions to solve and cure sickle cell disease, solve longevity & personalized medicine, provide high-quality and transparent healthcare at a reasonable cost, and accelerate research on aging reversal.

Our two organizations, which bring together their combined clinical and technical expertise in A.I machine learning and genetic analysis, will pursue this objective through a public-NGO and private endeavor that will be free from profit making constraints.

This combined effort will bring forth the incorporation of a new company in the U.S. who's mission and vision will remain the same as XBIOSPACE Lab's current mission: Health & Longevity Through Personalized Medicine and Biological Repair For All.

Rafael R. Vivas (Florida State University, Harvard) will be officially named Co-Founder & CEO while R. Midhun Krishna (NIT Rourkela, EPFL) will take the official title of Co-Founder & CINNO. Rima Martin and Rasif A.L will remain as CBDO and COO, Co-founders respectively.

The human clinical trial will take place at our new facility in the biotech and IT hub of Trivandrum, Kerala with technical support from Prof. B. P Nayak MD PhD at the NIT-Rourkela, India and XBIOSPACE Cambridge, MA facilities. Patients eligible for the trial will be recruited from The Sickle Cell Foundation eligible patient list in addition to their non-for-profit healthcare clinics in Cali, Valle Del Cauca, Colombia, and eventually throughout Latin American on a collaborated international effort.

The clinical trial will begin in the Summer of 2018 after independent ethics committee approval. The ethics

committee will be comprised by leading bioethics researchers at three of the leading Colombian Universities; La Universidad Nacional, Universidad de Los Andes, and La Pontificia Universidad Javeriana along with possible international collaborators from the U.S./Colombian NIH and JHU Bioethics; an effort to bringing in more international ethics committee members from other universities has been made and is ongoing.

The two leading and ongoing CRISPR human clinical trials at the Hangzhou Cancer Hospital and Stanford Medical School have been roped in an effort for transparency and scientific collaboration. Moreover, the Stanford Med human clinical trial team is set to start a CRISPR therapy on sickle cell disease patients this Spring.

The principal investigator for this human clinical trial will be Dr. Tulio Enrique Moreno MD, MSc. Dr. Moreno is a NIH Colombia, INS Colombia, Sickle Cell Disease clinician, and the Founder & CEO of The Colombian Sickle Cell Foundation.

Our CEO Rafael R. Vivas will be available for further comments as company representative on February 28th and March 7th, 2018 at 2018 MIT Harvard Ideaton 2018 competition, where we are finalist as the developers of the Crescent-Reishi™ Blockchain and API, and will be at The Future of DNA 2018 conference in San Francisco where we will make our final announcement on this upcoming project.

A second and third official press release on this endeavor will be made public at our website XBIO.SPACE on the dates of our MIT Harvard competition and at The Future of DNA 2018 events, respectively.

Lastly, let it be known that XBIOSPACE Labs will keep its original vision in becoming the world's best technology company by accelerating research on longevity & personalized medicine, beating George Church to successfully reverse aging on a human with a human clinical trial using CRISPR before the end of the next decade.

ABOUT XBIOSPACE LABS

XBIOSPACE is an Indian/U.S startup founded on transhumanist principles: The idea that the human condition can be transformed by developing and making sophisticated technologies and greatly enhance human intellect and physiology. For more information visit us xbio.space and follow us @vBLInnovation on twitter. Facebook page @ <https://www.facebook.com/xbiospace/>

XBIOSPACE LABS

info@xbio.space

xbio.space - Home page, Get in Touch

About La Fundación Integral Para La Drepanocitosis

Founded in 2004, La Fundacion Integral para La Drepanocitosis's mission: (Translated from Spanish) To provide comprehensive healthcare to individuals, families, and communities suffering from sickle cell disease or are at risk of presenting the disease through the assistance of a multidisciplinary team that helps individuals realize their aspirations in search for a cure, meet their needs to change or adapt to the environment, and to improve quality and life expectancy of our patients. For more information visit their

Facebook page @Fundación Integral para la Drepanocitosis/Anemia Falciforme.

The Foundation would also like to inform that their web page and email servers are currently down as they're being updated and will be available the start of the clinical trial.